Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

HANGZHOU and SHAOXING, China, Jan. 17, 2022. Ascletis Pharma Inc. announced today the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC22 (Envafolimab), a...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials